Selective targeting of the CCR5/CCL5 signaling also led to reduced tumor growth in experimental pancreatic adenocarcinoma through disruption of CCR5-dependent recruitment of regulatory T cells into tumors [22]. The gene discussed is CCR5; the disease is pancreatic adenocarcinoma.